Carvotroline (; developmental code name WY-47791) is a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist which was under development as a potential antipsychotic but was never marketed. It showed modest or moderate affinity for the dopamine D2 and serotonin 5-HT2 receptors and produced antipsychotic-like effects in animals. The drug was being developed by Wyeth. It reached phase 1 clinical trials prior to the discontinuation of its development. Carvotroline was first described in the scientific literature by 1991.
See also Substituted γ-carboline Gevotroline
References